Social Media Ideas for Amgen

Amgen's Growth Engine Is Just Getting Started

Amgen: A Biotech Giant's Path to Recovery and Growth

Join us as we dissect Amgen's stock performance and management strategies. Is this biotech giant poised for growth, or is it facing significant challenges ahead?

Amgen Turns to an Independent Review to Defend Rare Disease Drug in FDA Crosshairs

FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to w...

I work at amgen. ask me anthing. I'll answer honestly

I work at amgen. ask me anthing. I'll answer honestly Anonymous (not verified) Tue, 07/07/2026 - 09:09 field_thread_url https://cafepharma.com/boards/threa...

EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks

A European Medicines Agency committee now recommends withdrawing marketing authorization for Tavneos, an Amgen drug marketed in Europe by a CSL Limited subsidiary. Meanwhile, an FD...

The fall of Amgen

The fall of Amgen Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/the-fall-of-amgen.709419/...

Amgen, Sanofi Team Up To Urge En Banc Antibody IP Review

Rival pharmaceutical companies that squared off at the U.S. Supreme Court over antibody patents have jointly asked the full Federal Circuit to review an unrelated panel decision re...

After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset

Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over...

Amgen loses in Harbour antibody patent case, ordered to pay $20M+

A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidiary of China’s Harbou...

Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial

A Delaware federal jury decided Friday that Amgen Inc. and its Teneobio Inc. unit willfully infringed a mouse antibody patent asserted by Harbour Antibodies BV and others, and shou...

Argenx

Argenx Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Amgen Wins Order Blocking Colorado's Enbrel Price Cap

Colorado is preliminarily blocked from enforcing its price cap on Amgen's rheumatoid arthritis drug Enbrel, a federal judge ruled Wednesday, saying the biotech company is likely to...

FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med

Viridian Therapeutics’ Lumvoa is approved for treating both the chronic and active phases of thyroid eye disease. This drug will offer patients an alternative to Tepezza, an Amgen...

Sandoz's Patent Loss Blocks Antitrust Suit, 4th Circ. Told

Retired U.S. Circuit Judge Paul R. Michel is backing Amgen against Sandoz's Fourth Circuit appeal, arguing in an amicus brief that the final say over now-nixed allegations of block...

Argenx

Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

ANC

ANC Anonymous (not verified) Thu, 06/04/2026 - 17:44 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...

Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza

Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.

<![CDATA[Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics]]>

How Safe Is Amgen's Dividend?

Near-term headwinds could sink the stock, but there is more to the story.

Groups Tell 4th Circ. Not To Let Sandoz 'Relitigate' Enbrel

Pharmaceutical groups and the Washington Legal Foundation backed Amgen in amicus briefs Monday urging the Fourth Circuit not to revive Sandoz's antitrust claims, arguing that if Sa...

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sal...

Genmab

Genmab Anonymous (not verified) Mon, 07/13/2026 - 12:14 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...

FDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbuster

Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA.

Genmab

Genmab Anonymous (not verified) Thu, 07/02/2026 - 06:06 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...